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ABSTRACT 
Treatment of diabetes mellitus (DM) can be vary, using 
monotherapy or combination therapy, and it depends on the 
severity of the disease. That variation will give influences to the 
patient’s clinical condition and also their quality of life (QoL). The 
objective of this study is to determine the average of QoL’s score 
in DM patients who use monotherapy and combination therapy of 
antidiabetic oral in Public Health Center of Kotagede 1 
Yogyakarta. This study was conducted in a cross sectional  study. 
Subjects were people who had an age above 18, got the 
diagnose of DM type 2, and also consumed of oral antidiabetic 
monotherapy or combination. The measurement of QoL is using a 
DQLCTQ questionnaire in Bahasa Indonesia. Analysis statistic 
with independent sample T-test was used to determine the 
differences between QoL in patients who use monotherapy and 
combination. Subjects who met the inclusion criteria are 52 
patients. About  82.70% (43 patients) of the patients used 
combination and the other (9 patients) used monotherapy. The 
average of QoL in monotherapy patients (78.95±11.36) was 
higher than in combination therapy’s (75.18±10.57). Result of 
the analysis statistic showed that there is no significant 
differences (p0.095) of QoL between monotherapy and 
combination therapy patients. 
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INTRODUCTION 
Quality of life (QoL) is measured by 
individual perceptions on various aspects such 
as physical, emotional, and social aspect. The 
differences on each particular aspects 
influenced by ethnic, culture, education, and 
also income (Myers et al., 2013; Nagpal et al., 
2010). Other than that, quality of life also 
affected by chronic disease. Some studies 
showed that patients with chronic disease have 
an average of quality of life lower than healthy 
patients (Bonomi et al., 2000). 
Diabetes mellitus is a chronic disease 
that increase significantly year by year. Data 
from International Diabetes Federation in 2013 
showed that Indonesia was a country which 
have amount of people with diabetes (20-79 
years old) for about 8.5 millions (International 
Diabetes Federation, 2013). Different with that, 
according to International Diabetes Federation in 
2015, total cases of adults (20-79 years old) with 
diabetes is about 10 million cases (International 
Diabetes Federation, 2015). The increasing of 
amount of diabetes patients needs an attention 
from many people and adequate of 
management therapy, which are including self-
monitoring blood glucose, exercise, dietary 
modifications, and also adherence of the 
medications (Sharma et al., 2014). In order to 
get a better glycemic index, it requires 
appropriate therapeutic management, and also 
it can be a preventive from the complications 
and with the hope of increasing patient’s quality 
of life.       
Treatment of diabetes mellitus patients 
can be vary using monotherapy or combination 
therapy, and it depends on the severity of the 
disease from each person. The treatment that 
used by the patients will give influences to the 
patient’s clinical condition and also their quality 
of life. Previous study showed that the increase 
of complexity regimen in diabetes patients was 
needed to get a better glycemic control, 
however the measurement of QoL showed that 
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patients felt physical inconvenience caused by 
the increasing of complexity regimen (Lau et al., 
2004). 
There are many kinds of avalailable 
instruments for assessing quality of life, 
including generic and disease-specific which in 
this study is diabetes-specific. Generic 
instruments are designed to assess aspects on 
health that universal, and different with that, 
disease-specific instrument more detailed               
and accurate to measure specific impacts of 
health. The Diabetes Quality of Life Clinical 
Trial Questionnaire (DQLCTQ) is one of 
disease-specific instrument that has been 
validated, reliable and comprehensive to 
measure quality of life (Shen et al., 1999; Garratt 
et al., 2002).  
The objective of this study is to 
determine the average of quality of life’s score 
in diabetes mellitus patients who use 
monotherapy and combination therapy of 
antidiabetic oral in Public Health Center of 
Kotagede 1 Yogyakarta.    
 
MATERIAL AND METHODS 
Ethics Clearance was granted by the 
Ethics Committee of Ahmad Dahlan University 
with approval No.011601013. Informed 
consent paper was obtained from all 
participants. 
 
Study design 
This study was a cross sectional study 
which was conducted between February and 
March 2016 in Public Health Center of 
Kotagede 1 Yogyakarta, Indonesia. 
 
Participants 
The subjects on this study were diabetes 
mellitus patients’ who came to Public Health 
Center of Kotagede 1 between February – 
March 2016. The inclusion criterias of this 
study were patients who had an age above 18 
years old, got the diagnose of diabetes mellitus 
type 2 and attended to the public health center 
of Kotagede 1 Yogyakarta, consumed of oral 
antidiabetic monotherapy or combination, and 
also willing to be a participants. The exclusion 
criteria in this study was people who did not 
filled the questionnaire completely. The amount 
of patients that met the inclusion criterias was 
52 patients. 
Questionnaire 
Patients who met the inclusion criteria 
and willing to be a participant will get a 
questionnaire. Measurement of quality of life in 
this study using a Diabetes Quality of Life 
Clinical Trial Questionnaire (DQLCTQ) in 
Bahasa Indonesia version. DQLCTQ has 8 
aspects included physical, energy, health distress, 
mental health, satisfaction, treatment satisfaction, 
treatment flexibility, and frequency of symptoms. 
The measurement of quality of life in DQLCTQ 
questionnaire using a scale from 0 to 100, 
which are higher score indicates better quality 
of life. DQLCTQ questionnaire has been 
validated in previous study (Shen et al., 1999).  
 
Statistical Analysis 
Analysis statistic with independent 
sample T-test was used to determine the 
differences between quality of life in patients 
who use oral antidiabetic monotherapy and 
combination therapy.  
 
RESULT AND DISCUSSION 
A number of 52 patients who met the 
inclusion criteria have characteristics (Table I). 
Table I showed that 75% of patients (39) was 
female, and 50%  (26 patients) had ages over 60 
years old. Data on this study was different with 
data from IDF in 2013 which are about 14 
million more men than women with diabetes, 
and the ages of almost half of all adults with 
diabetes are between 40-59 years old 
(International Diabetes Federation, 2013). These 
differences can be occured due to the insufficient 
number of participants in this study. 
The types of medicine divided into 2 
groups which were monotherapy in 9 patients 
(17.3%) and combination therapy in 43 patients 
(82.7%). In diabetes mellitus, metformin is an 
optimal drug for monotherapy, however, if the 
monotherapy cannot reach the glycemic target, 
initial combination between metformin plus a 
second agent can be used to achieve the 
HbA1C target more quickly (Inzucchi et al., 
2015). These data also can be linked with the 
duration of the disease since diagnosis, which 
were 65.4% (34 patients) had disease duration 
since  more  than  3 years ago.  Besides that, the 
impact of diabetes mellitus is comorbidities, 
and 69.2% (36 patients) in this study have 
comorbidities.  
Imaniar Noor Faridah 
Volume 28 Issue 2 (2017)  121 
Table I. Patient’s characteristic 
 
Patient’s 
Characteristic 
Number of 
Patients n=52 (%) 
Sex  
Male 13 (25%) 
Female 39 (75%) 
Age  
   < 40  4 (7.70%) 
   41-60 22 (42.3%) 
   > 60 26 (50.0%) 
Educational Level  
   No education 9 (17.3%) 
   < Senior High School 26 (50.0%) 
   > Senior High School 17 (32.7%) 
Marietal status  
   Not married 1 (1.9%) 
   Married 37 (71.2%) 
   Divorce/Widow(ed) 14 (26.9%) 
Duration since diagnosis  
   < 1 year 1 (1.9%) 
   1-3 years 17 (32.7%) 
   > 3 years 34 (65.4%) 
Type of Medicine  
   Monotherapy 9 (17.3%) 
   Combination therapy 43 (82.7%) 
Comorbidities  
   Yes 36 (69.2%) 
   No 16 (30.8%) 
 
Table II showed about the use of 
antidiabetic oral in this study. A number of 43 
patients (82.70%) use combination therapy, 
which were all of them use metformin as a first 
therapy and  use sulphonylurea as an additional 
therapy. Metformin, a biguanides which can 
reduce the hepatic glucose, is the optimal drug 
for monotherapy. Its advantages were low cost, 
minimal side effect of hypoglycemia, and can 
reduce the CVD events (Inzucchi et al., 2015). 
The additional therapy were sulphonylurea 
including glimepiride and glibenclamid. The 
patients who use glimepiride was higher than 
glibenclamid. A randomized controlled trial 
study which compared the effect of glimepiride 
and glibenclamid on blood glucose in normal 
man showed that in fasting state there were 
similar effect on blood glucose level after IV 
administration of glibenclamid and glimepiride, 
and different with that, in post-prandial state 
(3-5h) blood glucose was significanly higher 
after glibenclamide than after glimepiride 
administration (Raptis et al., 1999).  
Table II. The use of antidiabetic oral in diabetes 
type 2 patients 
 
Medicines Sum % 
 Monotherapy 
  Metformin 8 15,38 % 
Glimepiride 1 1,92% 
Glibenclamid 0 0 
Total 9 17,30% 
Combination therapy 
  Metformin + Glimepiride 41 78,85% 
Metformin + Glibenclamid 2 3,85% 
Total 43 82,70% 
 
Quality of life analysis (Table III) 
showed that the average of quality of life in 
monotherapy patients was higher that in 
patients who use combination therapy, 
although that was not significantly different 
(p=0.095). The result of this study was               
similar with previous study in hospital of 
Yogyakarta in 2011, which the average of 
quality of life in monotherapy patients was 
higher than in combination therapy, and it was 
significantly different (p=0.002) (Sari et al., 
2011).  
The endpoints of diabetes mellitus from 
the UK Prospective Diabetes Study (UKPDS) 
are reducing the achieved HbA1C of 7.0% (for 
intensive treatment group) versus 7.9% (for 
conventional treatment group), reducing 
microvascular endpoints (retinopathy, 
nephropathy, and neuropathy), and decreasing 
the need of laser treatment and catarac surgery 
(UK Prospective Diabetes Study, 1998). If the 
use of monotherapy can reduce the blood 
glucose and find the target of glycemic index, 
patients will get the benefit and increase their 
quality of life.  
Furthermore, the result from table III 
showed that patients who use monotherapy had 
a good score in physical function, energy, 
health distress, mental health, satisfaction, 
treatment flexibility, and frequency of 
symptoms. It has been known that diabetes has 
negative impact on physical, psychological, and 
social functioning (Koopmanschap, 2002). 
Stress and coping with diabetes can affect the 
severity of the disease directly, also with 
pathophysiological processes and patient’s 
perception of illness will affect to the patient’s 
adherence and daily functioning. 
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There are 2 domains that different 
significantly, including physical function and 
treatment satisfaction domains. Physical 
function score in monotherapy patients was 
higher than in combination therapy patients, it 
can be happened because the monotherapy 
patients were not feel restricted in their daily 
activities. This differences were statistically 
different with the significant value 0.005 
(p<0.05).  
The use of combination treatment in 
diabetes mellitus type 2 patients is if non insulin 
monotherapy at maximal tolerated dose does 
not achieve or maintain HbA1C target over 3 
months. Other than that, increasing the 
physical activity also important to get the 
HbA1C target before adding another oral agent 
(ADA, 2016). Thus, patients who use 
combination therapy are patients who cannot 
maintain their glicemic index and needed 
additional treatment.   
Other, in the treatment satisfaction 
domain, the score of patients who use 
combination therapy was higher than 
monotherapy patients, and it was statistically 
different that proved by the significant value 
which is 0.008 (p<0.05). This data was different 
with the previous study, which were score of 
treatment satisfaction domain in combination 
therapy patients was lower than in 
monotherapy patients (p=0.645) (Sari et al., 
2011). The meaning of this result was 
combination therapy patients feel satisfied with 
their treatment.  
Combination therapy is given to patients 
who cannot adequately decrease the blood 
glucose with monotherapy. In this study, 
quality of life higher in combination therapy 
patients than in monotherapy, which means 
that patients can feel the positive impact from 
the combination therapy. Result from different 
study, in patients with unresectable or 
metastatic cutaneous BRAF Val600-mutation-
positive melanoma (COMBI-v) showed the 
results that treatment with combination of 
dabrafenib plus trametinib gives a benefit rather 
than with monotherapy vemurafenib (Grob 
2015).  
Furthermore, other domains such as 
energy, health distress, mental health, 
satisfaction, treatment flexibility, and frequency 
of symptoms were not different statistically 
between monotherapy and combination 
therapy patients. All of their score were            
higher in monotherapy than in combination 
therapy.       
Finally, limitation of this study was the 
insufficient number of participants and it made 
an impact to the quality of life’s score.  In order 
to improve this study, the number of 
participants should be increased and balanced 
between monotherapy and combination 
therapy patients. Others, a lot of factors                 
that can affect to the quality of life, such               
as comorbidity, absence of adverse event,    
Body Mass Index (BMI), or emotional           
patients which should be added in the next 
study.  
 
Table III. Analysis QoL between monotherapy and combination therapy 
 
Quality of Life Domain 
Type of therapy 
p value 
Monotherapy (n=9) Combination therapy (n=43) 
Physical Function 91.11+13.6 73.02+17.3 0.005* 
Energy 78.67+12.2 71.72+10.5 0.850 
Health Distress 81.78+8.02 78.60+9.9 0.376 
Mental Health 82.22+11.2 77.21+9.5 0.170 
Satisfaction 76.19+7.6 73.13+6.3 0.207 
Treatment Satisfaction 72.84+14.2 83.46+9.5 0.008* 
Treatment Flexibility 69.44+10.5 68.37+8.5 0.742 
Frequency of Symptoms 79.37+13.6 75.95+13.1 0.484 
Total QoL 631.62+90.92 601.46+84.6 0.095 
Average of QoL 78.95+11.36 75.18+10.57 0.095 
 
Note *= Significantly differences ( p < 0.05 ) 
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CONCLUSION 
From this study, we found that there is 
no significant differences (p 0.095) of quality of 
life between monotherapy patients and 
combination therapy patients.  
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